NCT03483012View on ClinicalTrials.gov

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

November 21, 2019

Study Completion Date

September 30, 2025

Conditions
Breast Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway

PROCEDURE

Stereotactic radiosurgery (SRS)

Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER